GLP-1 Drugs Like Zepbound Effectively Treat Sleep Apnea Alongside CPAP

A new review found that GLP-1s offer significant improvements in obstructive sleep apnea associated with obesity. vitapix/E+/Getty Images New research has found that GLP-1 drugs may improve obstructive sleep apnea (OSA) related to obesity. The effects of tirzepatide (Zepound), which is FDA approved for OSA, were especially notable. GLP-1s appear to improve OSA associated with obesity by promoting fat loss in the neck, throat, and tongue. CPAP therapy should be continued until a physician has confirmed remission with a sleep study. GLP-1 medications prescribed for weight loss, such as Zepbound and Wegovy, show promise for easing symptoms associated with sleep apnea. A new research review published in JAMA Otolaryngology on September 3 found that glucagon-like peptide-1 (GLP-1) receptor agonists may offer significant improvement in obstructive sleep apnea (OSA) related to obesity. The effects were especially true for tirzepatide (Zepbound, Mounjaro), which also acts on glucose-dependent insulinotropic polypeptide (GIP) receptors. Zepbound is already approved by the Food and Drug Administration (FDA) to help treat sleep apnea. The National Council on Aging explains that OSA occurs wh…

≈